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Abstract. Severe acute respiratory syndrome (SARS) 
coronavirus‑2 (SARS‑coV‑2), the causative viral agent for the 
ongoing cOVId‑19 pandemic, enters its host cells primarily 
via the binding of the SARS‑coV‑2 spike (S) proteins to the 
angiotensin‑converting enzyme 2 (AcE2). A number of other 
cell entry mediators have also been identified, including 
neuropilin‑1 (NRP1) and transmembrane protease serine 2 
(TMPRSS2). More recently, it has been demonstrated that 
transmembrane protease serine 4 (TMPRSS4) along with 
TMPRSS2 activate the SARS‑coV‑2 S proteins, and enhance 
the viral infection of human small intestinal enterocytes. 
To date, a systematic analysis of TMPRSS4 in health and 
disease is lacking. In the present study, using in silico tools, 
the gene expression and genetic alteration of TMPRSS4 
were analysed across numerous tumours and compared to 
controls. The observations were also expanded to the level of 
the central nervous system (CNS). The findings revealed that 
TMPRSS4 was overexpressed in 11 types of cancer, including 
lung adenocarcinoma, lung squamous cell carcinoma, 
cervical squamous cell carcinoma, thyroid carcinoma, 
ovarian cancer, cancer of the rectum, pancreatic cancer, 
colon and stomach adenocarcinoma, uterine carcinosarcoma 
and uterine corpus endometrial carcinoma, whilst it was 
significantly downregulated in kidney carcinomas, acute 
myeloid leukaemia, skin cutaneous melanoma and testicular 
germ cell tumours. Finally, a high TMPRSS4 expression was 
documented in the olfactory tubercle, paraolfactory gyrus and 
frontal operculum, all brain regions which are associated with 
the sense of smell and taste. collectively, these data suggest 
that TMPRSS4 may play a role in cOVId‑19 symptomatology 
as another SARS‑coV‑2 host cell entry mediator responsible 
for the tropism of this coronavirus both in the periphery and 
the cNS.
Introduction
Severe acute respiratory syndrome (SARS) coronavirus‑2 
(SARS‑coV‑2) is the causative viral agent for the ongoing 
cOVId‑19 pandemic, with >75 million infected individuals 
and >2.38 million deaths worldwide, up to the writing of the 
present study (February 14, 2021) (1,2). during the writing 
of the present manuscript, a glimpse of hope appeared on the 
horizon with vaccinations being developed and administered 
globally (3‑7).
It is now well‑established that the entry of SARS‑coV‑2 
into cells is facilitated by its spike (S) proteins, mainly 
through binding to the angiotensin‑converting enzyme 2 
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(AcE2) (8,9). Moreover, the SARS‑coV‑2 S proteins are 
primed/activated by the transmembrane protease serine 2 
(TMPRSS2), which appears to also play a key role in this 
viral infection (8,10,11). As such, there is increasing interest 
in identifying additional molecular mediators that may 
also facilitate the SARS‑coV‑2 infection of host cells and 
promote further adverse cOVId‑19 symptoms. Accordingly, 
neuropilin‑1 (NRP1) has been identified as a novel cellular 
mediator implicated in the SARS‑coV‑2 infection (12‑14), 
whilst similar evidence has also more recently emerged 
for TMPRSS4, another transmembrane protease. Indeed, 
TMPRSS4 ‑ along with TMPRSS2 ‑ appear to activate the 
SARS‑coV‑2 S proteins, and enhance subsequent viral 
infection of human small intestinal enterocytes (15). These 
data from Zang et al, provide evidence that the intestine is 
an additional target organ for SARS‑coV‑2 (15). Moreover, 
a recent study demonstrated that both AcE2 and TMPRSS2 
genes were abundantly expressed in enterocytes of the lower 
gastrointestinal (GI) tract, whilst also exhibiting co‑expres‑
sion with TMPRSS4, particularly in the small intestine (16). 
Of note, whereas cOVId‑19 presentation usually includes 
fever, cough, pulmonary/respiratory symptoms, and loss of 
taste and smell (17,18), an increasing number of studies has 
also reported GI‑related symptoms (e.g., diarrhoea, nausea 
and vomiting) in patients with cOVId‑19 (19‑21). Indeed, a 
proportion of these patients with extra‑pulmonary symptoms 
do not exhibit other respiratory symptoms (22).
Apart from respiratory and GI‑related symptoms, it is 
now evident that patients with cOVId‑19 may experience 
a wide repertoire of neurological symptoms and complica‑
tions (23‑28), suggesting that SARS‑coV‑2 can also attack 
the central nervous system (cNS), potentially via additional 
cell entry mediators, including NRP1 (14,29). Indeed, in silico 
analysis indicated that certain key mediators which facilitate 
the entry of SARS‑coV‑2 into host cells, including AcE2, 
cathepsin L (cTSL), TMPRSS2 and TMPRSS4, are expressed 
in the cNS, with the two transmembrane proteases being 
highly expressed in neurons (30).
Finally, increasing evidence suggests that cancer consti‑
tutes an additional risk factor for severe cOVId‑19 infection, 
with hospitalised patients with cOVId‑19 (particularly males 
and those receiving treatment with chemotherapy) exhibiting a 
poor prognosis and being associated with a high case‑fatality 
rate (31). The authors of the present study, as well as other 
researchers have documented the differential expression of 
SARS‑coV‑2 infection mediators in malignant states (11,32). 
TMPRSS2 in particular, was previously found to be signifi‑
cantly upregulated in rectum adenocarcinoma, as well as in 
prostate, breast and lung cancer (11). Notably, compared to 
never‑smokers, a similar AcE2 and TMPRSS2 expression, but 
a higher TMPRSS4 expression, has been found in the human 
bronchial epithelial cells of current smokers when compared 
to never‑smokers (33).
To date, there is a paucity of published data about the expres‑
sion profile of TMPRSS4 in cancer. Therefore, present study 
curated pan‑cancer data in terms of TMPRSS4 gene expres‑
sion using in silico approaches. The TMPRSS4 expression 
profile is also further expanded by providing more evidence 
regarding the presence of this transmembrane protease in the 
cNS and GI track.
Data and methods
Bioinformatics analysis. The expression analysis of TMPRSS4 
was validated through the Genotype‑Tissue Expression 
(GTEx, www.gtexportal.org) and GEPIA (gepia.cancer‑pku.
cn). Information regarding the TcGA cohort pan‑cancer data 
was acquired through cBioPortal (www.cbioportal.org/) and 
single cell analysis was done by using the Single cell Portal 
(singlecell.broadinstitute.org/single_cell). datasets accessed 
for pan‑cancer analysis were the following: Acc, adreno‑
cortical carcinoma; BLcA, bladder urothelial carcinoma; 
BRcA, breast invasive carcinoma; cESc, cervical squamous 
cell carcinoma and endocervical adenocarcinoma; cHOL, 
cholangiocarcinoma; cOAd, colon adenocarcinoma; dLBc, 
lymphoid neoplasm diffuse large B cell lymphoma; EScA, 
oesophageal carcinoma; GBM, glioblastoma multiforme; 
HNSc, head and neck squamous cell carcinoma; KIcH, 
kidney chromophobe; KIRc, kidney renal clear cell carci‑
noma; KIRP, kidney renal papillary cell carcinoma; LAML, 
acute myeloid leukaemia; LGG, brain lower grade glioma; 
LIHc, liver hepatocellular carcinoma; LUAd, lung adeno‑
carcinoma; LUSc, lung squamous cell carcinoma; MESO, 
mesothelioma; OV, ovarian serous cystadenocarcinoma; 
PAAd, pancreatic adenocarcinoma; PcPG, pheochromocy‑
toma and paraganglioma; PRAd, prostate adenocarcinoma; 
REAd, rectum adenocarcinoma; SARc, sarcoma; SKcM, 
skin cutaneous melanoma; STAd, stomach adenocarcinoma; 
TGcT, testicular germ cell tumours; THcA, thyroid carci‑
noma; THYM, thymoma; UcEc, uterine corpus endometrial 
carcinoma; UcS, uterine carcinosarcoma; and UVM, uveal 
melanoma. The visualisation of TMPRSS4 expression in the 
human brain was performed using the Allen brain atlas with 
6 human donors, as assessed by microarray and presented 
as a heatmap (34). These data were acquired from a publicly 
available source which underwent all appropriate approvals 
by the Human Investigation committees and Institutional 
Ethics committees of each institute from which samples were 
obtained.
Statistical analysis. The method used for differential analysis 
in the present study was one‑way ANOVA, using disease state 
(Tumour or Normal) as variables for calculating differential 
expression: Gene expression ~disease state. The expression 
data are first log2(TPM+1) transformed for differential anal‑
ysis and the log2FC is defined as median (Tumor) – median 
(Normal). Genes with higher |log2Fc| values and lower 
q values than pre‑set thresholds are considered differentially 
expressed genes. For more information please visit: http://gepia.
cancer‑pku.cn/help.html.
Results
Using the TcGA and GTEX datasets, it was demonstrated 
that, compared to the normal control, TMPRSS4 was upregu‑
lated in 11 cancer datasets (i.e., cESc, cOAd, LUAd, LUSc, 
OV, PAAd, REAd, STAd, THcA, UcEc and UcS) (Fig. 1), 
while it was significantly downregulated in 6 datasets (i.e., 
KIcH, KIRc, KIRP, LAML, SKcM and TGcT), with three 
of the latter consisting kidney tumours (i.e., KIcK, KIRc and 
KIRP) (Fig. 2).
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Furthermore, using the cBioportal pan‑cancer panel, the 
present study identified specific cancer types with a number of 
TMPRSS4 amplifications in LGG, LUAD, STAD, deep dele‑
tions in BRcA, HNSc, and shallow deletions in BLcA, BRcA, 
cESc, EScA, LUAd, LUSc, OV and TGcT. Furthermore, 
there were two datasets for thyroid cancers with a number of 
patients presenting diploid and not mutated versions of the 
gene, namely for THYM and THcA. Of note, in the majority 
of the studied cancers, the majority of the patients had dele‑
tions and partly some gains and amplifications (Fig. 3).
As aforementioned, there is emerging evidence suggesting 
abundant SARS‑coV‑2 infection of the GI tract in severe 
cOVId‑19 cases (35). Herein, these observations were 
expanded upon using single cell analysis from 51 cell subsets 
(366,650 cells in total) in the colon mucosa of 18 ulcerative 
colitis and 12 healthy individuals using the Single cell 
Portal (36). Using T‑distributed Stochastic Neighbour 
Embedding (tSNE) ‑ a machine learning algorithm for 
visualization ‑ distinct cell sub‑populations express TMPRSS4 
(Fig. 4). Notably, a high TMPRSS4 expression was noted in 
immature enterocytes, BEST4‑expressing enterocytes and 
enterocytes, as presented in Fig. 4c.
Finally, TMPRSS4 expression was also observed in various 
brain regions, based on a human microarray data set of 6 human 
brains (Fig. 5). These data were acquired from a publicly avail‑
able source which underwent all appropriate approvals by the 
Human Investigation committees and Institutional Ethics 
committees of each institute from which samples were obtained.
Figure 1. From the 33 TcGA cancer datasets, 11 exhibited a higher TMPRSS4 expression in tumour samples. TMPRSS4 was highly expressed in lung cancers 
(LUAd and LUSc), gynecological cancers (cESc, OV, UcEc and UcS), pancreatic carcinoma (PAAd), colon adenocarcinoma (cOAd), rectum carcinoma 
(REAd), stomach adenocarcinoma (STAd) and thyroid cancer (THcA). T, tumour; N, normal; TPM, transcripts per million; LUAd, lung adenocarcinoma; 
LUSc, lung squamous cell carcinoma; cESc, cervical squamous cell carcinoma and endocervical adenocarcinoma; OV, ovarian serous cystadenocarcinoma; 
UcEc, uterine corpus endometrial carcinoma; UcS, uterine carcinosarcoma.
Figure 2. Out of the 33 TCGA cancer datasets, TMPRSS4 was significantly downregulated in 6 datasets (i.e., KICH, KIRC, KIRP, LAML, SKCM and TGCT), 
with three of these consisting kidney tumours (i.e., KIcK, KIRc and KIRP) compared to normal tissues. KIcH, kidney chromophobe; KIRc, kidney renal clear 
cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukaemia; SKcM, skin cutaneous melanoma; TGcT, testicular germ cell 
tumours; T, tumour; N, normal.
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Fig. 5 presents these data as heatmaps of log2 expression 
values, showing that TMPRSS4 is expressed throughout 
the human brain. Of note, anosmia represents one of the 
common first symptoms of SARS‑CoV‑19 infection (37,38), 
Figure 3. cBioportal analysis of the 32 TcGA datasets with information about the gene dysregulation. In BLcA, LUAd and LUSc there are a number of 
shallow deletions, while in BRcA and HNSc, high expression and more deep deletions are observed. In gynaecological cancers (cESc, OV, UcEc and UcS), 
there is high expression of the TMPRSS4 and a few patients present Gains and Missense ‘variants of uncertain significant’ (VUS). BLCA, bladder urothelial 
carcinoma; BRcA, breast invasive carcinoma; cESc, cervical squamous cell carcinoma and endocervical adenocarcinoma; HNSc, head and neck squamous 
cell carcinoma; LUAd, lung adenocarcinoma; LUSc, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; UcEc, uterine corpus endo‑
metrial carcinoma; UcS, uterine carcinosarcoma.
Figure 4. Single cell analysis of colon mucosa, using the Single cell Portal, revealed widespread expression of TMPRSS4. (A) Single‑cell transcriptomics 
data are displayed as a spectral tSNE (T‑distributed Stochastic Neighbour Embedding) plot of 366,650 cells, annotated according to known cell types; 
(B) sub‑populations of cell types which are enriched for TMPRSS4 expression, with expression intensity demonstrated by a heat map; (c) single cell analysis 
using the Single cell Portal, enriched for population subtypes, represented as violin plots. Notably, high TMPRSS4 expression was noted in immature entero‑
cytes, BEST4‑expressing enterocytes and enterocytes. TA1, TA2; transit‑amplifying (TA) cells.
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and although there is global brain expression of TMPRSS4, 
a high TMPRSS4 expression is noted in brain regions impor‑
tant for the sense of smell and taste, namely in the olfactory 
tubercle (Log2 expression, 2.1±1), paraolfactory gyrus (Log2 
expression, 1.3±0.3) and frontal operculum (Log2 expression, 
1.5±0.5). These Log2 expression values are provided by the 
Allen Brain Atlas. Previous research has also demonstrated 
that TMPRSS4 exhibited the highest expression in neurons, 
with the neuronal rich cerebral cortex exhibiting a high 
TMPRSS4 expression (39). TMPRSS4 protein expression 
is 1.5 protein‑transcripts per million (pTPM) in this region 
with the highest expression localised to the neuronal cells 
(ProteinAtlas_ENSG00000137648).
Discussion
In the present study, comprehensive evidence is presented 
regarding the peripheral tissue and cNS distribution of a 
new potential mediator of SARS‑coV‑2 infection, namely 
TMPRSS4. Of note, it was demonstrated that TMPRSS4 is over‑
expressed in lung cancer; a condition that predisposes to severe 
COVID‑19 (33,40,41). The current findings are in agreement 
with those of a previous study demonstrating the co‑expression 
of TMPRSS4 with other key SARS‑coV‑2 cell entry mediators 
(i.e., AcE2, AdAM17 and TMPRSS2) in bronchial epithelial 
cells from never smokers and current smokers (33). Notably, 
that study also demonstrated that the TMPRSS4 levels were 
elevated in smokers, suggesting that this may be an additional 
risk factor for SARS‑coV‑2 infection (33). In the lung cancer 
cohorts investigated in the present study, a marginal difference 
was note in LUAd with a marked downregulation of TMPRSS4 
in current smokers, whilst in patients with LUSc an increase 
in TMPRSS4 was noted in smokers compared to non‑smokers 
(Fig. S1A and B). This is suggestive of potential tissue‑specific 
effects, given that patients with LUAd have poorer prognosis 
than those with LUSc (42).
Another recent study also demonstrated a high expression 
of TMPRSS4 in the human endometrium, which increased 
with age, particularly in the early phases of the cycle (43). This 
is of increasing importance given that SARS‑coV‑2 infectivity 
increases with age (44). The present study expanded on these 
observations and provided evidence of TMPRSS4 expression 
in other gynaecological tissues, demonstrating that TMPRSS4 
is expressed in the cervix, vagina, fallopian tubes, ovaries, 
breast and uterus, with the first two being the primary organs 
in terms of a high expression (Fig. S1d). Moreover, it was 
demonstrated that TMPRSS4 was significantly upregulated in 
gynaecological malignancies, namely cESc, OV, UcEc and 
UcS. As age appears to play a role in the risk of cOVId‑19, the 
present study further investigated the expression of TMPRSS4 
in the above‑mentioned malignancies with age. In this respect, 
TMPRSS4 expression increased with age only in the case of 
UcEc (Fig. S1c). One of the major limitations of the present 
study was that in silico data were accessed, that did not allow 
us to perform statistical analysis with a post hoc test. Another 
limitation is the absence of survival analysis data. Future 
studies are required to determine whether TMPRSS4 can be 
of prognostic value in terms of overall‑ and/or progression free 
survival.
Recently, two different groups have described the involve‑
ment of TMPRSS4 as a SARS‑coV‑2 entry mediator in the 
GI (15,16). In particular, AcE2, TMPRSS2 and TMPRSS4 
Figure 5. Heatmap expression of TMPRSS4 in the brains of 6 human donors, as assessed by microarray (Allen brain atlas). Global brain expression of TMPRSS4, 
as detected by microarray probes, with expression of cerebral areas indicated on the hemispheres and expression in brain nuclei indicated as dots. Heatmaps of 
expression are displayed below individual brains and organised by anterior to posterior regions with the frontal lobe (Fl), hippocampal formation (HiF), occipital 
lobe (Ol), parietal lobe (Pl), temporal lobe (Tl), striatum (Str), dorsal thalamus (dT), cerebral cortex (cbcx) and myelencephalon (MY) marked on the heatmap.
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have been shown to be co‑expressed primarily in the small 
intestine (16). In another study, through a series of elegant 
experiments, it was shown that, apart from TMPRSS2, 
TMPRSS4 also enhanced SARS‑coV‑2 infectivity in gut 
epithelial cells (15), suggesting that a leaky gut may allow 
SARS‑coV‑2 to spread to other organs, including the liver. 
Future studies are required to focus on the role of these key 
cell entry mediators in GI tract organs, particularly in relation 
to extra‑pulmonary manifestations of severe cOVId‑19.
Finally, it was demonstrated that TMPRSS4 is present in 
a number of anterior and posterior regions of the brain. This 
corroborates previous finding indicating expression in the 
cerebral cortex, hippocampus and caudate (45). Of note, other 
SARS‑coV‑2 cell entry mediators (e.g., AcE2, TMPRSS2, 
NRP1 and cTSL) are also expressed in the cNS, raising the 
possibility of a synergy between multiple such proteins which 
may further drive the SARS‑coV‑2 neurotropism (29,30,46).
In conclusion, the present study documents widespread 
TMPRSS4 protein expression in the cNS and GI tract, and 
provides further evidence supporting the potential involve‑
ment of TMPRSS4 in facilitating adverse cOVId‑19 
outcomes in patients with certain cancers. collectively, these 
data suggest that TMPRSS4 may be implicated in the symp‑
tomatology/complications of cOVId‑19, acting as another 
SARS‑coV‑2 cell entry mediator responsible for the tropism 
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